Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-05-12 1:57 pm Sale | 13D | Regulus Therapeutics Inc. RGLS | Growth Equity Opportunities V LLC | 1,945,579 9.99% | -12,636,942 (-86.66%) | View |
| 2023-05-10 09:58 am Purchase | 13G | Regulus Therapeutics Inc. RGLS | FEDERATED HERMES INC. FHI | 3,875,578 19.9% | 970,752 (+33.42%) | View |
| 2023-02-01 11:43 am Sale | 13G | Regulus Therapeutics Inc. RGLS | FEDERATED HERMES INC. FHI | 2,904,826 17.25% | -26,143,439 (-90.00%) | View |
| 2023-01-31 1:51 pm Sale | 13G | Regulus Therapeutics Inc. RGLS | VICTORY CAPITAL MANAGEMENT INC | 850,197 5.05% | -7,653,446 (-90.00%) | View |
| 2022-10-11 09:03 am Purchase | 13G | Regulus Therapeutics Inc. RGLS | FMR LLC | 2,195,000 14.998% | 2,195,000 (New Position) | View |
| 2022-05-16 2:35 pm Purchase | 13G | Regulus Therapeutics Inc. RGLS | FEDERATED HERMES INC. FHI | 29,048,265 19.9% | 29,048,265 (New Position) | View |
| 2022-02-14 4:33 pm Sale | 13G | Regulus Therapeutics Inc. RGLS | Point72 Asset Management L.P. | 2,411,577 1.6% | -3,215,436 (-57.14%) | View |
| 2022-02-14 2:30 pm Sale | 13G | Regulus Therapeutics Inc. RGLS | Altium Capital Management LP | 1,729,780 2.1% | -1,500,000 (-46.44%) | View |
| 2022-02-14 2:15 pm Sale | 13G | Regulus Therapeutics Inc. RGLS | EcoR1 Capital LLC | 2,538,970 1.7% | -1,111,110 (-30.44%) | View |
| 2022-02-14 1:05 pm Purchase | 13G | Regulus Therapeutics Inc. RGLS | BIOTECHNOLOGY VALUE FUND L P | 9,661,235 9.99% | 2,610,771 (+37.03%) | View |
| 2022-02-02 09:55 am Unchanged | 13G | Regulus Therapeutics Inc. RGLS | VICTORY CAPITAL MANAGEMENT INC | 8,503,643 5.83% | 0 (Unchanged) | View |
| 2022-01-04 12:37 pm Sale | 13G | Regulus Therapeutics Inc. RGLS | VICTORY CAPITAL MANAGEMENT INC | 8,503,643 5.83% | -15,599 (-0.18%) | View |
| 2021-12-09 2:58 pm Purchase | 13D | Regulus Therapeutics Inc. RGLS | Growth Equity Opportunities V LLC | 14,582,521 9.99% | 12,530,067 (+610.49%) | View |
| 2021-03-08 11:05 am Purchase | 13G | Regulus Therapeutics Inc. RGLS | VICTORY CAPITAL MANAGEMENT INC | 8,519,242 12.73% | 8,519,242 (New Position) | View |
| 2021-02-12 7:23 pm Purchase | 13G | Regulus Therapeutics Inc. RGLS | BIOTECHNOLOGY VALUE FUND L P | 7,050,464 9.99% | 4,953,756 (+236.26%) | View |
| 2021-02-12 5:11 pm Unchanged | 13G | Regulus Therapeutics Inc. RGLS | Altium Capital Management LP | 3,229,780 6.8% | 0 (Unchanged) | View |
| 2021-02-12 4:15 pm Purchase | 13G | Regulus Therapeutics Inc. RGLS | EcoR1 Capital LLC | 3,650,080 5.4% | 1,327,436 (+57.15%) | View |
| 2020-12-09 5:13 pm Purchase | 13G | Regulus Therapeutics Inc. RGLS | Point72 Asset Management L.P. | 5,627,013 8.5% | 5,627,013 (New Position) | View |
| 2020-02-14 5:19 pm Purchase | 13G | Regulus Therapeutics Inc. RGLS | BIOTECHNOLOGY VALUE FUND L P | 2,096,708 9.99% | 1,044,768 (+99.32%) | View |
| 2020-02-14 1:51 pm Unchanged | 13G | Regulus Therapeutics Inc. RGLS | Altium Capital Management LP | 3,229,780 9.99% | 0 (Unchanged) | View |